PT2789348T - Lipossomas e método de produção correspondente - Google Patents
Lipossomas e método de produção correspondenteInfo
- Publication number
- PT2789348T PT2789348T PT128230950T PT12823095T PT2789348T PT 2789348 T PT2789348 T PT 2789348T PT 128230950 T PT128230950 T PT 128230950T PT 12823095 T PT12823095 T PT 12823095T PT 2789348 T PT2789348 T PT 2789348T
- Authority
- PT
- Portugal
- Prior art keywords
- liposomes
- production method
- corresponding production
- production
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT10605011 | 2011-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2789348T true PT2789348T (pt) | 2021-11-11 |
Family
ID=47681975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT128230950T PT2789348T (pt) | 2011-12-07 | 2012-12-07 | Lipossomas e método de produção correspondente |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9393320B2 (pt) |
| EP (1) | EP2789348B1 (pt) |
| CA (1) | CA2858741C (pt) |
| PT (1) | PT2789348T (pt) |
| WO (1) | WO2013084208A2 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6825764B2 (ja) * | 2014-08-14 | 2021-02-03 | エル.イー.エー.エフ. ホールディングス グループ エルエルシーL.E.A.F. Holdings Group Llc | リポソームカプセル化親和性薬物 |
| EP3158992A1 (en) * | 2015-10-21 | 2017-04-26 | Universität Heidelberg | Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules |
| WO2017105344A1 (en) * | 2015-12-17 | 2017-06-22 | Nanyang Technological University | Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them |
| CN110548152A (zh) * | 2018-05-30 | 2019-12-10 | 复旦大学 | 一种穿膜抗炎肽修饰的肿瘤靶向多药共载脂质体及其制备方法 |
| EP3628309A1 (en) | 2018-09-28 | 2020-04-01 | Universität Heidelberg | Method of making oral dosage forms |
| CN118203546A (zh) | 2019-05-07 | 2024-06-18 | 米尼翁大学 | 生产脂质体的方法 |
| WO2020240445A1 (en) * | 2019-05-27 | 2020-12-03 | Association For The Advancement Of Tissue Engineering And Cell Based Technologies & Therapies A4Tec - Associação | Phosphatidylcholine liposomes for use in autoimmune diseases |
| CN116178702A (zh) * | 2023-03-06 | 2023-05-30 | 河南大学 | 一种叶酸靶向的新材料、叶酸靶向tgx221脂质体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| AU769569B2 (en) | 1998-12-18 | 2004-01-29 | Alza Corporation | Method of administering a compound to multi-drug resistant cells |
| AU2003216445A1 (en) * | 2002-02-27 | 2003-09-09 | The Medical College Of Ohio | Therapeutic methods for acute myeloid leukemia |
| US20050191344A1 (en) * | 2004-01-15 | 2005-09-01 | Samuel Zalipsky | Liposome composition for delivery of therapeutic agents |
| WO2007006041A2 (en) | 2005-07-05 | 2007-01-11 | Purdue Research Foundation | Imaging and therapeutic method using monocytes |
| US20100226967A1 (en) * | 2006-05-23 | 2010-09-09 | Purdue Research Foundation | Imaging and therapeutic method using progenitor cells |
| GR1006666B (el) | 2006-07-21 | 2010-01-19 | Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος" | Μοριακοι δενδριτικοι φορεις με προσαρμοζομενη/μεταβαλλομενη διαλυτοτητα και συμπληρωματικοτητα προς μεμβρανικους υποδοχεις |
| CN101684177A (zh) | 2009-05-27 | 2010-03-31 | 沈阳药科大学 | 叶酸偶联聚乙二醇聚烷基氰基丙烯酸酯及制法和应用 |
| WO2010143193A1 (en) | 2009-06-11 | 2010-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Targeted liposomes comprising n-containing bisphosphonates and uses thereof |
-
2012
- 2012-12-07 CA CA2858741A patent/CA2858741C/en active Active
- 2012-12-07 PT PT128230950T patent/PT2789348T/pt unknown
- 2012-12-07 EP EP12823095.0A patent/EP2789348B1/en active Active
- 2012-12-07 WO PCT/IB2012/057083 patent/WO2013084208A2/pt not_active Ceased
- 2012-12-07 US US14/363,698 patent/US9393320B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2789348B1 (en) | 2021-08-04 |
| EP2789348A2 (en) | 2014-10-15 |
| WO2013084208A2 (pt) | 2013-06-13 |
| US20140335164A1 (en) | 2014-11-13 |
| CA2858741C (en) | 2018-07-31 |
| US9393320B2 (en) | 2016-07-19 |
| WO2013084208A3 (pt) | 2013-11-07 |
| CA2858741A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL230394A (en) | Machine and method of making beverage | |
| GB201107863D0 (en) | Method and product | |
| EP2728213A4 (en) | TELESCOPIC SHAFT AND MANUFACTURING METHOD THEREFOR | |
| PL2760619T3 (pl) | Sposób wytwarzania struktury | |
| GB201113087D0 (en) | Method | |
| GB201116248D0 (en) | Liposome production using isopropanol | |
| GB201118985D0 (en) | Product and method | |
| GB201113610D0 (en) | Product and method | |
| ZA201308690B (en) | Axle and production method | |
| PT2789348T (pt) | Lipossomas e método de produção correspondente | |
| SG11201402998PA (en) | Hydroxy-aminopolymers and method for producing same | |
| EP2636771A4 (en) | CRYSTAL METHOD | |
| EP2698159A4 (en) | PITAVASTATE-CONTAINING PREPARATION AND METHOD OF MANUFACTURING THEREOF | |
| GB201105436D0 (en) | Method | |
| EP2727484A4 (en) | BRACELET AND METHOD FOR PRODUCING THE SAME | |
| GB201112447D0 (en) | Method | |
| EP2737065A4 (en) | PROCESS FOR PRODUCING PROTEINS | |
| GB201114919D0 (en) | Method | |
| GB201114325D0 (en) | Method | |
| GB201101219D0 (en) | Method | |
| GB201111189D0 (en) | Method | |
| GB201107931D0 (en) | Manufacturing method and product | |
| GB201105245D0 (en) | Electrodeposition method and product obtained thereby | |
| GB201111673D0 (en) | Method | |
| GB201108041D0 (en) | Method |